Docket Number:10A-990625
Inventor:Wu H. C., Li P. C., Chiu C. Y.
IP Status:US 8637035, TW I 448552
Abstract:
Dengue virus (DENV), the pathogen behind dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), remains a public health treat in tropical and subtropical regions of the world. In this study, we have newly generated thirty-two MAbs against dengue virus type 2 (DENV-2). Six MAbs could be used efficiently to neutralize DENV-2 infection.
Fields of Application:
- Development of diagnostic reagents for dengue patients.
- Development of therapeutic antibodies against dengue virus type
Advantages when compared to the existing technologies:
To our knowledge, the neutralizing monoclonal antibodies (MAbs) we generated are the most potent neutralizing MAbs against DENV-2 so far. These neutralizing MAbs showed a significant therapeutic effect for mice challenged with lethal dose of DENV-2. These MAbs are valuable for development of diagnostic reagents and therapeutic antibodies against DENV-2.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
